|
|
Gene Symbol |
GSTP1 |
|
Aliases |
DFN7, FAEES3, GST3, GSTP, HEL-S-22, PI |
|
Entrez Gene ID |
|
|
Gene Name |
Glutathione S-transferase pi 1 |
|
Chromosomal Location |
11q13.2 |
|
HGNC ID |
|
|
Summary |
Glutathione S-transferases (GSTs) are a family of enzymes that play an important role in detoxification by catalyzing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione. Based on their biochemical, immunologic, and structural properties, the soluble GSTs are categorized into 4 main classes: alpha, mu, pi, and theta. This GST family member is a polymorphic gene encoding active, functionally different GSTP1 variant proteins that are thought to function in xenobiotic metabolism and play a role in susceptibility to cancer, and other diseases. [provided by RefSeq, Jul 2008]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
|
|
e!Ensembl
|
Protein Information |
|
Protein Name |
Glutathione S-transferase P, GST class-pi, GSTP1-1, deafness, X-linked 7, epididymis secretory protein Li 22, fatty acid ethyl ester synthase III |
|
Function |
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration. |
|
|
|
|
|
UniProt |
|
|
PDB |
1LBK, 10GS, 11GS, 12GS, 13GS, 14GS, 16GS, 17GS, 18GS, 19GS, 1AQV, 1AQW, 1AQX, 1EOG, 1EOH, 1GSS, 1KBN, 1MD3, 1MD4, 1PGT, 1PX6, 1PX7, 1ZGN, 20GS, 22GS, 2A2R, 2A2S, 2GSS, 2J9H, 2PGT, 3CSH, 3CSI, 3CSJ, 3DD3, 3DGQ, 3GSS, 3GUS, 3HJM, 3HJO, 3HKR, 3IE3, 3KM6, 3KMN, 3KMO, 3N9J, 3PGT, 4GSS, 4PGT, 5DAK, 5DAL, 5DCG, |
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000257555 |
P20823 |
P20823 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Cardiovascular Diseases |
Hypertensive disease |
|
Myocardial Ischemia |
|
Acute Coronary Syndrome |
|
Digestive System Diseases |
Non-alcoholic Fatty Liver Disease |
|
Liver Diseases |
|
Hepatitis |
|
Ear Or Mastoid Diseases |
Vestibular disorder |
|
Endocrine System Diseases |
PCOS |
|
Neoplasms |
Prostate cancer |
|
Stomach Cancer |
|
Glioma |
|
Anaplastic Carcinoma |
|
Bladder Cancer |
|
Breast Cancer |
|
Carotid Atherosclerosis |
|
Myeloid Leukemia |
|
Lung Cancer |
|
Prostatic Intraepithelial Neoplasias |
|
Gastric Cancer |
|
Sarcoma |
|
Renal Cancer |
|
Lymphoma |
|
Carcinoma |
|
Hodgkin Disease |
|
Osteosarcoma |
|
Liver Cancer |
|
Vulvar Cancer |
|
Nervous System Diseases |
Tremor |
|
Carotid Artery Diseases |
|
Moyamoya disease |
|
Neuropathy |
|
Lateral Sclerosis |
|
Parkinson Disease |
|
Psychiatric/Brain disorders |
Schizophrenia |
|
Psychosis |
|
Non-organic psychosis |
|
Shared Paranoid Disorder |
|
Autistic Disorder |
|
Renal Disorder |
Ureteral Calculi |
|
Kidney Failure |
|
Kidney Calculi |
|
Kidney Insufficiency |
|
Respiratory Tract Diseases |
Asthma |
|
Skin and Connective Tissue Diseases |
Dermatitis |
|
|
References |
|
|
Galazis Nicolas, Pang Yik-Lam, Galazi Myria, Haoula Zeina, Layfield Robert, Atiomo William |
Nottingham Medical School, University of Nottingham, Queen's Medical Centre Campus Nottingham University Hospital, Nottingham, UK. ngalazis@gmail.com |
Gynecol Endocrinol. 2013 Jul;29(7):638-44. doi: 10.3109/09513590.2013.777416. |
Abstract
There is a need for research studies into the molecular mechanisms underpinning the link between polycystic ovary syndrome (PCOS) and endometrial cancer (EC) to facilitate screening and to encourage the development of novel strategies to prevent disease progression. The objective of this review was to identify proteomic biomarkers of EC risk in women with PCOS. All eligible published studies on proteomic biomarkers for EC identified through the literature were evaluated. Proteomic biomarkers for EC were then integrated with an updated previously published database of all proteomic biomarkers identified so far in PCOS women. Nine protein biomarkers were similarly either under or over expressed in women with EC and PCOS in various tissues. These include transgelin, pyruvate kinase M1/M2, gelsolin-like capping protein (macrophage capping protein), glutathione S-transferase P, leucine aminopeptidase (cytosol aminopeptidase), peptidyl-prolyl cis-transisomerase, cyclophilin A, complement component C4A and manganese-superoxide dismutase. If validated, these biomarkers may provide a useful framework on which the knowledge base in this area could be developed and will facilitate future mathematical modelling to enhance screening and prevention of EC in women with PCOS who have been shown to be at increased risk. |
|
|
|
|
| © 2019, Biomedical Informatics Centre, NIRRH |
National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai-400 012
Tel: 91-22-24192104, Fax No: 91-22-24139412
|